# A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

> **NCT07043751** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 216 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** TQB6411 injection

## Key facts

- **NCT ID:** NCT07043751
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043751, "A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07043751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*